FISCHER MEDICAL VENTURES LIMITED
(Formerly known as Fischer Chemic Limited)
Registered Office Address: Survey No. 480/2 AP Medtech Zone,
Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032
CIN: L86900AP1993PLC118162
Email: cs@fischermv.com | Website: www.fischermv.com | Contact 9080966548

September 3, 2026

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001.
BSE Scrip Code: 524743

National Stock Exchange of India Ltd.
Exchange Plaza, 5tll floor
Plot No. C/ 1, G Block,
Bandra-Kurla Complex Bandra (E),
Mumbai - 400 051.
NSE Symbol: FISCHER

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 3rd September, 2026

Pursuant to Regulation 30 & 33 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have inter-alia approved and taken on record the following at its meeting held today (03/09/2026):

Appointment of Independent Director:

Approved the appointment of Mr. David Yeow as the Additional Independent Director (DIN: 11923054) with effect from 3rd September 2026. Details as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 are enclosed herewith as Annexure-1.

Reconstitution of Audit Committee:

Pursuant to appointment of Independent Director, the Board has approved the reconstitution of the Audit Committee of the Board. Details as required under Regulation30 of the SEBI (LODR) Regulations, 2015 are enclosed herewith as Annexure 2.

33rd Annual General Meeting:

The 33rd Annual General Meeting ('AGM') of the Members of the Company will be held on Tuesday, 29th September 2026 through video conferencing or other audio-visual means at 11.00 AM IST.

Considered & approved the appointment of M/s Nuren Lodaya & Associates Practicing Company Secretary, Mumbai as Scrutinizer of the Annual General Meeting, to scrutinize the e-voting and remote e-voting process in a fair and transparent manner.

FISCHER MEDICAL VENTURES LIMITED
(Formerly known as Fischer Chemic Limited)
Registered Office Address: Survey No. 480/2 AP Medtech Zone,
Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032
CIN: L86900AP1993PLC118162
Email: cs@fischermv.com | Website: www.fischermv.com | Contact 9080966548

<u>Closure of Register of Members:</u>
Please note that the share transfer books of the Company will remain closed 23/09/2026 (Wednesday) to 29/09/2026 (Tuesday) (both days inclusive).

The Board Meeting commenced at 11:15 AM (IST) and concluded at 02:20 PM (IST)

Please take on record.

Thanking You,
Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**

BALAJI GANDLA Digitally signed by BALAJI GANDLA Date: 2026.09.03 14:28:02 +05'30'

Fischer Medical Ventures Limited

BALAJI GANDLA
COMPANY SECRETARY AND COMPLIANCE OFFICER

ANNEXURE – 1

Details under Regulation 30 of the Listing Regulations read with SEBI Circular No. EBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Name	**MR. DAVID YEOW**
DIN	11923054
Reason for change viz. appointment, reappointment, resignation, removal, death or otherwise	Appointment of Mr. David Yeow (DIN: 11923054), as an Additional Non-Executive Independent Director of the Company
Date of appointment/re-appointment/cessation (as applicable) & term of appointment/reappointment	Appointment of Mr. David Yeow (DIN: 11923054), as an Additional Non-Executive Independent Director of the Company, not liable to retire by rotation, for a first term of five consecutive years effective from September 3, 2026, subject to the approval of Shareholders.
Term of appointment/reappointment;	5 years
Brief profile (in case of appointment)	Mr. David Yeow, is an accomplished engineer from Singapore, is business leader and technology commercialisation professional with over three decades of experience across manufacturing, quality systems, global supply chain management, technology transfer and innovation. He holds a Diplôme d'Ingénieur (equivalent to M.Eng.) in Electronic Engineering from the École Nationale Supérieure d'Électronique et de Radioélectricité de Bordeaux, France, and is a GE-certified Six Sigma Blackbelt. He has held senior leadership positions with GE Plastics, Lanxess and NTUitive, where he led technology assessment, commercialisation and technology transfer initiatives. He currently serves as Principal at Hunniwell Lake Ventures, a medical device venture capital firm. He has also served on the boards of several technology-driven companies.
Disclosure of relationships between Directors	Mr. David Yeow is not related to any other Director of the Company.
Information as required pursuant to BSE Circular ref. no. LIST/COMP/14/2018-19 and NSE ref. no. NSE/ML/2018/24 dated June 20, 2018.	Mr. David Yeow is not debarred from holding the office of Director by virtue of any SEBI Order or any such authority.

ANNEXURE-2

Audit Committee:

S no	Name of the Director	Status	Category
1	Mr. Khairy Jamaluddin Abu Bakar	Chairman	Independent Director
2	Ms. Jaya Ankur Singhania	Member	Independent Director
3	Mr. Chan Sing En	Member	Independent Director
4	Dr. Syed Jalaludin	Member	Independent Director
5	Mr. Ravindran Govindan	Member	Executive Director
6	Ms. Svetlana Rao Raviwada	Member	Whole Time Director
7	Mr. David Yeow	Member	Independent Director